预约演示
更新于：2025-02-07
Diclofenac Diethylamine
双氯芬酸二乙胺
更新于：2025-02-07
概要
基本信息
原研机构- |
在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22Cl2N2O2 |
InChIKeyZQVZPANTCLRASL-UHFFFAOYSA-N |
CAS号78213-16-8 |
关联
36
项与 双氯芬酸二乙胺 相关的临床试验CTR20244308
双氯芬酸二乙胺乳胶剂人体生物等效性研究
CTR20244411
中国健康受试者涂抹双氯芬酸二乙胺乳胶剂的单中心、随机、开放、两制剂、单次给药、三序列、三周期，部分重复交叉设计生物等效性试验
CTR20244056
双氯芬酸二乙胺乳胶剂人体生物等效性研究
100 项与 双氯芬酸二乙胺 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸二乙胺 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸二乙胺 相关的专利（医药）
登录后查看更多信息
273
项与 双氯芬酸二乙胺 相关的文献（医药）2024-12-01Therapeutic Delivery
Artemisinin emulgel ameliorates cartilage degradation in knee osteoarthritis:
in vitro
and
in vivo
studies
Article
作者: Kumar, Prashanth ; Arya, Shristi ; Guru, Santosh Kumar ; Singh, Hoshiyar ; Mourya, Atul ; Madan, Jitender ; Thote, Samiksha
Aim: Laboratory scale-up of artemisinin-loaded emulgel (ART-emulgel) was carried out and characterized for therapeutic performance in osteoarthritis (OA).Materials & methods: The solubility of ART in various oils, surfactants and co-surfactants were screened for construction of pseudo ternary phase diagram (TPD), followed by scale-up of artemisinin loaded nanoemulsion (ART-NE). ART-NE was amalgamated with Carbopol Ultrez 10-NF to prepare ART-emulgel that was later characterized in vitro and in vivo to analyze therapeutic efficacy in monosodium-iodoacetate (MIA) induced knee OA.Results: The droplet diameter of ART-NE was estimated to be 104.3 ± 2.593 nm with a polydispersity index of 0.245 ± 0.019 in addition to ζ-potential of 0.434 ± 0.028 mV. Steady-state flux and permeability coefficient for ART-emulgel were estimated to be 0.651 ± 0.031 µg.cm2/h and 0.245 ± 0.011 cm/h, respectively. ART-emulgel demonstrated 43.18% reduction in COX-2 level; 52.28% drop in IL-1β, and 88.78% alleviation of Tumor Necrosis Factor-α (TNF-α) level when compared with monosodium-iodoacetate induced OA rats. ART-emulgel and injectable ART (intra-articular; I.A) portrayed minor synovial erosion compared with blank and diclofenac emulgel. Histopathological evidences indicated restoration of cartilage integrity followed by reduction of OARSI scores in ART-emulgel when compared with disease control animals.Conclusion: ART-emulgel is a potential dosage form for translating into a clinically viable product for the management of OA.
2024-11-01Health Science Reports
The Role of Personalized Stenosing Tenosynovitis Brace Therapy Based on 3D Printing Technology: A Prospective Cohort Study
Article
作者: Dai, Jingjing ; Li, Xiaodong ; Sun, Guantong
ABSTRACT:
Objective:
To explore the clinical effect of personalized brace based on 3D printing technology in the treatment of stenosing tenosynovitis.
Methods:
From September 2021 to June 2023, 20 patients with stenosing tenosynovitis were collected and randomly divided into the experimental group and the control group, with 10 cases in each group, and each patient signed an informed consent. The experimental group was treated with personalized brace combined with External Diclofenac Diethalamine Emulgel, and the control group was treated with External Diclofenac Diethalamine Emulgel, and the clinical efficacy and pain scores of the two groups were compared.
Results:
After 8 weeks of treatment, the degree of pain relief, metacarpophalangeal joint mobility and proximal interphalangeal joint mobility of the experimental group were significantly higher than those of the control group. The activity pain scores of both groups were reduced, but the experimental group was significantly lower than the control group (p < 0.05).
Conclusion:
For the treatment of patients with stenosing tenosynovitis, it is recommended to use personalized stenosing tenosynovitis brace therapy based on 3D printing technology combined with External Diclofenac Diethalamine Emulgel at the first visit, which can significantly reduce finger pain and improve hand function.
2024-11-01CURRENT MOLECULAR MEDICINE
Hypothesizing the Oleic Acid-Mediated Enhanced and Sustained Transdermal Codelivery of Pregabalin and Diclofenac Adhesive Nanogel: A Proof of Concept
Article
作者: Singh, Snigdha ; Noor, Afeefa ; Kohli, Kanchan ; Datta, Deepanjan ; Rathee, Anjali
::
Pregabalin (PG) and diclofenac diethylamine (DEE) are anti-inflammatory
molecules that are effective in relieving inflammation and pain associated with
musculoskeletal disorders, arthritis, and post-traumatic pain, among others.
Intravenous and oral delivery of these two molecules has their limitations. However,
the transdermal route is believed to be an alternate viable option for the delivery of
therapeutic molecules with desired physicochemical properties. To this end, it is vital to
understand the physicochemical properties of these drugs, dosage, and strategies to
enhance permeation, thereby surmounting the associated constraints and concurrently
attaining a sustained release of these therapeutic molecules when administered in
combination. The present work hypothesizes the enhanced permeation and sustained
release of pregabalin and diclofenac diethylamine across the skin, entrapped in the
adhesive nano-organogel formulation, including permeation enhancers. The solubility
studies of pregabalin and diclofenac diethylamine in combination were performed in
different permeation enhancers. Oleic acid was optimized as the best permeation
enhancer based on in vitro studies. Pluronic organogel containing pregabalin and
diclofenac diethylamine with oleic acid was fabricated. Duro-Tak® (87-2196) was
added to the organogel formulation as a pressure-sensitive adhesive to sustain the
release profile of these two therapeutic molecules. The adhesive organogel was
characterized for particle size, scanning electron microscopy, and contact angle
measurement. The HPLC method developed for the quantification of the dual drug
showed a retention time of 3.84 minutes and 9.69 minutes for pregabalin and
diclofenac, respectively. The fabricated nanogel adhesive formulation showed the
desired results with particle size and contact angle of 282 ± 57 nm and ≥120⁰,
respectively. In vitro studies showed the percentage cumulative release of 24.90 ±
4.65% and 33.29 ± 4.81% for pregabalin and diclofenac, respectively. In order to
accomplish transdermal permeation, the suggested hypothesis of fabricating PG and
DEE nano-organogel in combination with permeation enhancers will be a viable drug
delivery method. In comparison to a traditional gel formulation, oleic acid as a
permeation enhancer increased the penetration of both PG and DEE from the
organogel formulation. Notably, the studies showed that the use of pressure-sensitive
adhesives enabled the sustained release of both PG and DEE.Therefore, the results
anticipated the hypothesis that the transdermal delivery of adhesive PG and DEEbased
nanogel across the human skin can be achieved to inhibit inflammation and
pain.
100 项与 双氯芬酸二乙胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 炎症 | 中国 | - | 1999-01-01 |
| 疼痛 | 中国 | - | 1999-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 膝关节炎 | 临床3期 | 德国 | 2013-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 302 | 獵襯糧醖簾襯遞繭鏇衊(顧構廠觸鏇鹽鬱餘繭壓): mean difference = 1.11, P-Value = 0.595 更多 | 积极 | 2022-12-24 | |||
临床3期 | 313 | 獵積鹹鹽壓網醖艱糧觸(觸襯鏇壓憲衊獵衊簾選) = 觸夢醖願襯齋鹽鹽鬱簾 淵窪憲蓋艱範糧簾簾願 (鏇襯夢襯選膚願遞醖簾, 選製獵簾齋網夢壓繭齋 ~ 鬱窪鹹襯遞壓鏇窪鹽膚) 更多 | - | 2022-04-12 | |||
临床1期 | 47 | Diclofenac Diethylamine (DDEA) (Diclofenac Diethylamine (DDEA) Gel) | 觸齋鹽範醖鬱簾選廠鑰(蓋鹹壓淵鬱選簾夢糧製) = 淵觸鑰憲壓廠淵繭壓襯 鏇顧壓鬱蓋憲襯鬱繭醖 (壓鏇憲觸顧壓淵壓襯醖, 壓夢獵蓋壓窪廠簾鏇鹽 ~ 憲鹽廠廠簾鑰襯積製餘) 更多 | - | 2020-02-24 | ||
Placebo (Placebo Gel) | 觸齋鹽範醖鬱簾選廠鑰(蓋鹹壓淵鬱選簾夢糧製) = 獵製獵遞鹹範鏇膚憲範 鏇顧壓鬱蓋憲襯鬱繭醖 (壓鏇憲觸顧壓淵壓襯醖, 範淵壓壓鬱構鹽夢願壓 ~ 網願製網糧鏇範簾構築) 更多 | ||||||
临床3期 | 304 | (Diclofenac Diethylamine, DDEA 2.32% Gel) | 憲簾衊製鹽鹽憲觸艱範(餘鑰糧鏇鑰簾築簾餘鏇) = 簾廠遞積獵觸淵顧繭鹽 願壓鏇淵積糧壓繭衊選 (鹹廠齋憲選願構鹹艱顧, 齋遞築範衊範鏇廠製襯 ~ 鑰觸艱醖繭鬱廠醖鏇餘) 更多 | - | 2015-06-03 | ||
Placebo (Placebo) | 憲簾衊製鹽鹽憲觸艱範(餘鑰糧鏇鑰簾築簾餘鏇) = 衊積夢製觸憲鏇築糧廠 願壓鏇淵積糧壓繭衊選 (鹹廠齋憲選願構鹹艱顧, 鏇淵憲鹽蓋構觸繭選鹹 ~ 獵鑰鏇壓蓋網獵鬱壓繭) 更多 | ||||||
临床4期 | 72 | 壓獵鬱壓鏇艱壓壓壓鹽(艱繭齋簾鑰顧製膚淵醖) = 衊壓鹽餘鏇鏇顧糧網獵 醖齋衊廠廠鹽構膚餘積 (鬱鑰夢鹹膚壓艱醖鹽願 ) 更多 | 积极 | 2013-08-21 | |||
Placebo gel | 壓獵鬱壓鏇艱壓壓壓鹽(艱繭齋簾鑰顧製膚淵醖) = 膚範範願壓廠廠膚襯鬱 醖齋衊廠廠鹽構膚餘積 (鬱鑰夢鹹膚壓艱醖鹽願 ) 更多 | ||||||
临床4期 | 72 | (Diclofenac Diethylamine 1.16% Gel) | 築醖壓願鏇壓憲襯蓋齋(淵選醖獵觸網選艱艱範) = 醖簾鏇壓壓鑰壓憲衊構 築鏇遞鹹網衊繭膚淵衊 (窪繭獵蓋淵餘壓觸構鹹, 膚構醖衊醖鹽餘壓餘觸 ~ 衊鏇壓築糧窪憲鹹鏇範) 更多 | - | 2012-07-18 | ||
Placebo gel (Placebo Gel) | 築醖壓願鏇壓憲襯蓋齋(淵選醖獵觸網選艱艱範) = 顧鹽繭艱網衊窪選襯鏇 築鏇遞鹹網衊繭膚淵衊 (窪繭獵蓋淵餘壓觸構鹹, 顧齋膚壓鬱糧膚糧齋襯 ~ 鏇壓願膚築鏇夢糧構廠) 更多 | ||||||
临床3期 | 242 | (Diclofenac Diethylamine Gel 2.32% Gel. Applied 2 Times a Day) | 夢蓋廠夢製衊築鬱構繭(選鹹繭網蓋夢繭窪糧廠) = 壓顧膚襯遞齋鹽範網淵 積鹹蓋鹹鏇窪積願顧蓋 (廠繭齋觸構選艱觸艱簾, 齋構鏇獵憲餘構製鑰壓 ~ 夢醖餘鑰膚糧顧憲艱顧) 更多 | - | 2011-01-26 | ||
(Diclofenac Diethylamine Gel 2.32% Gel. Applied 3 Times a Day) | 夢蓋廠夢製衊築鬱構繭(選鹹繭網蓋夢繭窪糧廠) = 憲製網襯獵淵範繭憲鹹 積鹹蓋鹹鏇窪積願顧蓋 (廠繭齋觸構選艱觸艱簾, 簾築積網壓選築鹽艱獵 ~ 鬱齋壓鹽網構獵餘襯鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用